Market Overview

Cerus Announces Deal with Swiss Red Cross for Initial Deployment of INTERCEPT Blood System

Share:
Related CERS
Wedbush Securities Expects In-Line Financials For Cerus
4 More Biotech Secondaries Investors Are Watching

Cerus Corporation (NASDAQ: CERS) announced today that it has signed a two-year purchase agreement with two regional Swiss Red Cross Blood Services for deployment of the INTERCEPT Blood System for plasma in Lausanne and Zurich. These two pilot centers supply an estimated 15,000 plasma units annually.

Posted-In: News

 

Related Articles (CERS)

Get Benzinga's Newsletters